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ARSTRACT 
Objectives: To verify the clinical value of two different poly- 
merase chain reactions (PCRs) for noninvasive diagnosis and 
follow-up during Pneumocystis carinii f. sp. hominis pneumonia 
(PCP) and to analyze the P carinii f. sp. hominis genotypes 
involved. 
Methods: Internal transcribed spacers (ITSs) nested PCR was 
applied to 630 samples (bronchoalveolar lavage, sera, periph- 
eral blood mononuclear cells, and oropharyngeal samples) from 
122 patients with acquired immunodeficiency syndrome and 
pneumonia and 40 control samples from 20 subjects sero- 
negative for human immunodeficiency virus. One hundred and 
eighty samples also were examined by mt-rRNA PCR. Bron- 
choalveolar lavage samples and 33 sera were analyzed by 
type-specific oligonucleotide hybridization. 
Results: On bronchoalveolar lavage samples, the two PCRs 
consistently confirmed the morphologic diagnosis of PCP. The 
sensitivity of ITSs nested PCR versus mt-rRNA PCR was 57.3% 
versus 14.3% on sera, 32.3% versus 22.8% on peripheral 
blood mononuclear cells, and 69.1% versus 48.6% on oro- 
pharyngeal samples (garglings). Both PCRs had 100% speci- 
ficity. Type-specific oligonucleotide hybridization revealed in 
72.2% of bronchoalveolar lavage samples a single P carirtii f. 
sp. hominis genotype, whereas in 27.8% co-infection with more 
than one strain was detected. 
Conclusion: On noninvasive samples, ITSs nested PCR was 
more sensitive than mt-rRNA PCR, and it confirmed the 
diagnosis in all patients with PCP. For each patient with PCP 
at least one noninvasive sample was positive for F! carinii f. sp. 
hominis DNA. 
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In absence of lung biopsy, the gold standard for Pneu- 
mocystis carinii f. sp. hominis pneumonia (PCP) diag- 
nosis is the direct demonstration of the microorganism 
in induced sputum or in bronchoalveolar lavage (BAL). 
Sampling patients by either induced sputum or BAL can 
be difficult, especially in patients with severe respiratory 
distress. Several authors have used biomolecular tech- 
niques to detect the presence of l? carinii f. sp. hominis 
DNA by the polymerase chain reaction (PCR) of specific 
genomic regions. 1~2,3 The internal transcribed spacers 
(ITSs) nested PCR followed by type specific oligonu- 
cleotide (TSO) hybridization of I? carinii f. sp. hominis 
isolates derived from BAL. and blood samples represents 
a further tool to study P carinii f. sp. hominis virulence 
and drug susceptibility related to various genotypes.* The 
purpose of this study was to compare the sensitivity and 
specificity of two different PCR assays to detect l? carinii 
f. sp. hominis in samples taken from patients via several 
methods. 
MATERIAL AND METHODS 
From April 1995 to September 1997, 122 patients sero- 
positive for human immunodeficiency virus (HIV), from 
the 2nd Department of Infectious Diseases at L. Sacco 
Hospital in Milan, Italy, were enrolled in the study. Human 
immunodeficiency virus-seropositive patients were clin- 
ically evaluated for acute respiratory disease, characterized 
by at least two of the following features: cough, dyspnea, 
elevated serum lactate dehydrogenase level, arterial 
hypoxia, and chest x-ray abnormalities showing intersti- 
tial pneumonia. Patients with respiratory disease were 
examined by bronchoscopy for evidence of Pneumo- 
cystis carinii f. sp. hominis organisms. Blood (for serum 
and peripheral blood mononuclear cells [PBMC]) and 
oropharyngeal washes were collected on the same day 
before bronchoscopy. For each patient with BAL mor- 
phologically positive for I! carinii f. sp. hominis, addi- 
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tional blood samples were collected during follow-up. 
Clinical data, concomitant opportunistic infections (with 
special regard to fungi), and use of primary PCP pro- 
phylaxis, were determined by reviewing hospital records. 
Samples collected from 20 subjects working as health 
care personnel in the ward were used as controls. 
Samples were collected and processed as follows: 
Serum. From 7-mL blood samples, withdrawn by ster- 
ile Vacutainer (Becton Dickinson Vacutainer Systems) 
venipuncture into tubes containing clotting gelatin, 
serum was aliquoted in cryovials and stored at -80°C 
within 4 hours from collection. 
Peripheral Blood Mononuclear Cells. Cells were sep- 
arated from 7-mL blood samples, collected into Vacu- 
tainer heparinized tubes, by a Ficoll-Paque PLUS 
(Amersham Pharmacia Biotech, Uppsala, Sweden) gra- 
dient in RPMI-1640 with 20 mM Hepes (HyQ, 
HyClone Europe Ltd., Cramlington, United Kingdom). 
Cells were washed twice in RPMI, resuspended in 
1 mL of phosphate buffered saline, aliquoted in cryo- 
preservation Nalgene vials and stored at -80°C until 
used. / 
Oropharyngeal Samples (Garglings). Ten milliliters of 
sterile normal saline were gargled in the morning for 
about 2 minutes, aliquoted, and stored at -80°C until 
used. 
Bronchoalveolar Lavage. At least 5 mL of BAL were 
collected and separated within 12 hours from bron- 
choscopy and stored at -80°C until used. 
For DNA preparation, samples were processed as fol- 
lows: 250 pL of each sample were digested in 250 FL of 
proteinase K buffer (50 mM KCl; 15 mM Tris-HCI, pH 8.3; 
and 0.5% NP40) containing 0.2 mg/mL proteinase K 
(Boehringer Mannheim GmbH, Mannheim, Germany) at 
56°C for 2 hours; the enzyme was then inactivated by 
boiling for 10 minutes. DNA was extracted with phenol- 
chloroform, precipitated in ethanol, resuspended in 50 
FL TE buffer, and purified through columns (MicroSpin 
S200HR columns, Amersham Pharmacia Biotech). Sterile 
water was used as extraction control. 
Ten microliters of each sample were amplified with 
nested PCR using specific primers for ITSs of rRNA5: 
1724F (5’~AAG’ITGATCAAATTTGGTC-3’) and ITS2R (5’- 
CTCGGACGAGGATCCTCGCC-3’) for the first step (35 
cycles, denaturation at 94°C for 1 minute, annealing at 
47°C for 1 minute, and extension at 72°C for 1 minute); 
ITSlF (5’-CGTAGGTGAACCTGCGGAAGGATC-3’) and 
ITS2Rl (5’-GTTCAGCGGGTGATCCTGCCTG-3’) for the 
second step (35 cycles, denaturation at 94°C for 1 minute, 
annealing at 58°C for 1 minute, extension at 72°C for 2 
minutes). One hundred and eighty samples were also 
amplified with single-step PCR, using speciBc primers for 
mt-rRNA6: pAZ102-E (5’-GATGGCTG’MTCCAAGCCCA-3’) 
and pAZ102-H (5’-GTGTACGTTGCAAAGTACTC-3’) (40 
cycles, denaturation at 94°C for 1 minute 30 seconds, 
annealing at 50°C for 1 minute 30 seconds, and extension 
at 72°C for 2 minutes). Polymerase chain reaction controls 
were run with each clinical sample, by using deionized 
water as negative and a well-characterized P carinii DNA 
as positive control. Amplified products were elec- 
trophoresed on 6% acrylamide gel and stained with ethid- 
ium bromide. The expected size of PCR products was 
550 base pairs (bp) for ITSs and 346 bp for mt-rRNA 
(PhiX174 DNA HAE II marker, Amersham Pharmacia 
Biotech). 
Polymerase chain reaction products were hybridized 
(dot blot)‘as follows: denaturation with 0.4 N NaOH; blot- 
ting on Nytran paper; prehybridization overnight at 37°C 
with 100 l.@mL salmon sperm DNA (SIGMA Chemicals, 
St. Louis, MO) in 6~ SCC, 5X Denhart’s solution, 0.5% SDS, 
0.05% Na*P,O,; hybridization with pA2 102-L2 probe for 
mt-rRNA PCR,’ and IA, lB, 2a, 2b, 2c probes for ITSs 
nested PCR, according to TSO typing as detailed by Lu et 
al,* at high stringency conditions. Either 32P-radiolabelled 
or biotinylated probes were used, with signal detection 
obtained by using the Phototop@ Detection Kit (New Eng- 
land BioLabs Inc., Beverly, ME). To read the results, the 
membranes were exposed to Kodak autoradiography film. 
RESULTS 
After bronchoscopy, 68 of 122 (55.7%) patients were 
found to have PCP defined by the clinical presentation 
and the presence of trophic or cystic forms of I? carinii 
f. sp. hominis on BAL after Giemsa and toluidine-blue 
staining. A total of 54 (44.3%) of the patients had other 
AIDS-related opportunistic diseases: recurrent bacterial 
pneumonia (principally due to Klebsiella pneumoniae, 
Staphylococcus aureus, Pseudomonas aeruginosa, 
Xanthomonas maltophilia, Haemophilus injluenzae, 
Streptococcus pneumoniae), tuberculosis, atypical 
mycobacteriosis, cytomegalovirus infection, aspergillosis, 
and non-Hodgkin lymphoma. Candida spp oropharyn- 
geal co-infection was present in 51 of 68 (75%) patients 
with PCP and in 43 of 54 (79.6%) patients with other 
opportunistic diseases. The authors examined, by ITSs 
nested PCR, 630 samples (122 BALs, 220 sera, 126 PBMC, 
and 162 garglings): 374 samples (68 BALs, 146 sera, 81 
PBMC, and 79 garglings) were collected from 68 patients 
with AIDS (mean age, 35.6 y, range, 26-48 y; mean CD4+, 
Table 1. Main Clinical Features of Patients Included in the Study 
Patients Male Female CD4+ Age Oropharyngeal 
(n = 122) (n) (n) (cells/mm3) (y) Candidiasis n (%) 
PCP+* (68) 60 8 49.2 35.6 51 (75.0) 
PCP-+ (54) 44 10 107.3 34.6 43 (79.6) 
PCP = Pneumocystk carinii f. sp. hominis pneumonia. 
*HIV+ patients with bronchoalveolar lavage = proven PCP; +HIV+ patients with 
other pulmonary diseases. 
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Table 2. Sensitivity and Specificity of Internal Transcribed Spacers 
(ITSs) Nested vs. mt-rRNA Polymerase Chain Reaction (PCR) 
/E’s Nested PCR mt-rRNA PCR 
PcP+* PCP-+ PCP+* PCP-+ 
(n = 68) (%) (n = 54) (%) (n = 35) (%) (n = 70) 
BAL+ 68 (100.0) 5 (9.2)* 35 (I 00.0) 0 
Sera+ 39 (57.3) 0 5 (14.3) 0 
PBMC+ 22 (32.3) 0 8 (22.8) 0 
Garglings+ 47 (69.1) 0 17 (48.6) 0 
PCP = Pneumocystis carinii f. sp. hominis pneumonia; BAL = bronchoalveolar 
lavage; PBMC = peripheral blood mononuclear cells. *HIV+ patients with 
BAL proven PCP; +HIV+ patients with other opporiunistic pulmonary diseases: 
*PCR positivity only after the second step of amplification. 
49.2/mm3, range, 2-220 mm3) with morphologic diagno- 
sis of PCP 216 control samples (54 BALs, 54 sera, 45 
PBMC, and 63 garglings) from 54 patients with AIDS 
(mean age, 34.6 y, range 23-46 y; mean CD4+, 107.3/mm3, 
range 2-500 mm3) with morphologically negative BAL 
for l? carinii f. sp. hominis (Table l), and another 40 con- 
trol samples (20 sera and 20 garglings) from 20 HlV-neg- 
ative subjects working as health care personnel in the 
ward. The authors also examined, by mt-t-RNA PCR, 180 
samples (45 BALs, 45 sera, 45 PBMC, and 45 garglings) col- 
lected from 35 of 68 patients affected by PCP and from 
10 of 54 PCP-negative patients. Internal transcribed spac- 
ers nested PCR demonstrated the presence of I! carinii 
f. sp. hominis DNA in 73 of 122 (59.8%) BALs: in 68 
patients the results concurred with the direct morpho- 
logic diagnosis. In contrast, BALs from five patients yielded 
detectable levels of Pneumocystis carinii f. sp. hominis 
DNA even though the samples were negative by micro- 
scopic examination. Since these patients, during 3 months 
of follow-up, did not develop PCP in absence of IT carinii 
therapy and prophylaxis, it is possible that these were 
asymptomatic carriers. 
The ITSs nested PCR detected the presence of I! 
carinii f. sp. hominis DNA in 191 of 306 (62.4%) non- 
BAL samples collected from patients with PCP: 59 of 79 
(74.7%) garglings, 91 of I46 (62.3%) sera, and 41 of 81 
(50.6%) PBMC were positive. At least one positive serum 
was noted in 39 of 68 (57.3%) patients with PCP: 22 of 
68 (32.3%) had positive PBMC and 47 of 68 (69.1%) had 
positive oropharyngeal washes. All noninvasive samples 
from 54 HIV-positive patients with morphologically neg- 
ative BAL for l? carinii f. sp. hominis and from 20 healthy 
subjects were negative (specificity 100%). At the same 
time, the application of mt-rRNA PCR on 35 positive BALs 
confirmed, in all the cases, the morphologic diagnosis of 
PCl? In contrast, after mt-rRNA PCR, 5 of 35 (14.3%) 
patients with PCP had positive serum, 8 of 35 (22.8%) 
positive PBMC, and 17 of 35 (48.6%) positive oropha- 
ryngeal washes, whereas control samples from 10 PCP 
patients were negative (Table 2). 
Among patients with positive serum for P carinii f. 
sp. hominis DNA, 10 received aerosol pentamidine (300 
mg/mo) as primary prophylaxis and four received cotri- 
moxazole (960 mg/d). Twenty-five patients did not 
receive any prophylaxis during 6 months prior to the 
acute episode of PCl? Prophylaxis against E! carinii of all 
patients involved in the study is detailed in Table 3. 
Serum samples collected during the follow-up 
showed that the presence of Pcarinii f. sp. hominis DNA 
was limited to the first 8 to 12 days after the initiation of 
chemotherapy. During antipneumocystis chemotherapy, 
a rapid disappearance (less than 5 days) of serum E! 
carinii f. sp. hominis-DNA was observed in patients 
promptly recovering from PCP These data suggest a pos- 
sible relation between detection of Pcarinii f. sp. hominis 
DNA in serum and severity of PCP (Table 4). 
Type-specific oligonucleotide hybridization revealed 
the presence of 69 E! carinii f. sp. hominis isolates in 54 
of 68 BAL samples (Table 5). In 14 of 68 BALs it was not 
possible to define I? carinii f. sp. hominis genotype 
because of the lack of hybridization at ITS1 or ITS2 
sequences. Nine of 14 samples were then analyzed by 
cloning and sequencing and revealed new ITS types, as 
previously reported.& In 15 of 54 (27.8%) patients with 
PCP, TSO hybridization demonstrated the presence of 
more than one E! carinii f. sp. hominis genotype, sug- 
gesting a co-infection. 
Comparing the results obtained after TSO hybridiza- 
tion on 28 BALs and 33 sera collected from 25 patients 
during 28 episodes of PCP (25 prime episodes and 3 
relapses), the authors detected in I6 of 28 BALs a single 
E! carinii f. sp. hominis genotype and in 12 of 28 a co- 
infection with more than one I! carinii f. sp. hominis 
genotype. Besides, in 4 of 12 co-infections, perfect cor- 
respondence was noted between the I? carinii f. sp. 
hominis genotype detected on BAL and the one in serum. 
In contrast, for 8 of 12 patients the P carinii f. sp. 
hominis genotype detected in serum only partially 
matched the one detected on BAL (Table 6). Genotype 
Table 3. Prophylaxis in 122 Patients, Scored according to Bronchoalveolar Lavage Morphology 
Examination and Pneumocystis carinii f. sp. hominis DNA Serum Detection 
BAL Morphology* and DNA Serum Detection+ 
Prophylaxis BAL+; DNA Serum+ 
(n = 122) (100%) (n = 39) (32%) 
Cotrimoxazole (960 mg/d) (n = 51) (41.8) 4 (3.3) 
Pentamidine aerosol (300 mg/mo) (n = 38) (31 .l) 10 (8.2) 
None 25 (20.5) 
BAL = bronchoalveolar lavage. *By Giemsa and toluidine blue: +by ITSs nested PCR. 
BAL+; DNA Serum- BAL-; DNA Serum- 
(n = 29) (23.8%) (n = 54) (44.3%) 
18 (14.8) 29 (23.7) 
7 (5.7) 21 (17.2) 
4 (3.3) 4 (3.3) 
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Table 4. Clearance of Serum Pneumocystis carinii f. sp. hominis 
DNA Correlated to the Beginning of Chemotherapy in 39 Patients 
Number of Patients 
with PCP 
Days from Mild Severe Total 
Beginning of (n = 26) (n = 13) (n = 39) 
Chemotherapy (66.7%) (33.3%) (100.0%) 
<5 20 (51.3) 3 (7.7) 23 (59.0) 
B-10 5 (12.8) 4 (10.2) 9 (23.1) 
>lO 1 (2.6) 6 (15.4) 7 (17.9) 
PCP = Pfleumocystis carhii f. sp. hominis pneumonia. 
Mild PCP: 450 UI > LDH >I000 UI ; arterial p0, > 70 mmHg at diagnosis. 
Severe PCP: LDH z 1000 UI; arterial PaO, i 70 mmHg at diagnosis. 
LDH = lactate dehydrogenase. 
analysis performed during three relapses revealed the 
presence of either the same genotype or a different one 
(Table 7). 
DISCUSSION 
Several authors have reported the possible application 
of various PCR techniques for the detection of I? carinii 
f. sp. hominis on various biologic samples collected from 
patients affected by PCF! 1~2,3 The purpose of the present 
study was to compare the sensitivity and specificity of 
two different PCRs (ITSs vs. mt-t-RNA PCR) applied on 
BAL and noninvasive samples (blood and oropharyngeal 
washes) collected from AIDS patients with PCP When 
applied to BALs, the sensitivity of the two techniques 
gave similar results, as expected after the experimental 
detection of two versus three I? carinii nuclei for mt- 
rRNA (multicopy gene) PCR and ITSs (single or double 
copy gene) nested PCR, respectively9~10 
All cases of PCP confirmed by microscopic diagno- 
sis were observed to be positive by ITSs nested PCR and 
mt-rRNA PCR of BAL samples. Five morphologically neg- 
ative BALs had detectable levels of Pcarinii f. sp. hominis 
DNA, confirmed by TSO typing, in repeated controlled 
experiments. The authors suggest that asymptomatic car- 
riers of I? carinii f. sp. hominis exist, as confirmed in 
patients recovering from actual pneumonia with cepho- 
taxime or tobramycin therapy, the absence of overt PCP 
during 3-month follow-up, in the absence of antipneumo- 
cystis chemotherapy and prophylaxis, and the presence 
of a detectable level of I? carinii f. sp. hominis DNA (after 
the second step of PCR). This finding underscores the 
Table 5. Type-Specific Oligonucleotide Hybridization: 
Typing of 69 Pneumocystis carinii f. sp. hominis Isolates 
in 54 Bronchoalveolar Lavage Samples 
Number of 
Isolate (n = 69) (%) 
isolates Ab AC Ba Bb Bc 
69 (100%) 5 (7.2) 16 (23.2) 9 (13.1) 18 (26.1) 21 (30.4) 
Table 6. Results after internal Transcribed Spacers (ITSs) 
Nested Polymerase Chain Reaction (PCR) and Type-Specific 
Oligonucleotide Typing in Case of Single /? carinii f. sp. 
hominis Infection (l,ll,lll) and Co-infection (IV, V, VI) 
Patient Serum Day of ITSs Nested P. carinii f. sp. 
Number Specimen Therapy PCR hominis Types 
I Serum 0 + Bc 
BAL 0 + Bc 
Serum +2 - 
II Serum -5 + AC 
BAL 0 + AC 
Serum +I1 - 
Ill Serum -2 + Ba 
BAL -1 + Ba 
Serum +8 - 
Serum +I5 - 
IV BAL 0 + ABabc 
Serum i-11 + Ba 
V BAL 0 + ABac 
Serum +2 + Ba 
Serum +I4 
VI BAL 0 + ABC 
Serum +3 + AC 
Serum +6 
BAL = bronchoalveolar lavage. 
importance of evaluating these data. The hypothesis of 
the existence of asymptomatic carriers of E! carinii f. sp. 
hominis among AIDS patients has been suggested by 
other authors also.“,‘* Further research is needed to 
define the necessity of new adequate chemoprophylac- 
tic or therapeutic approaches. 
Results obtained from serum samples revealed that 
ITSs nested PCR was more sensitive than mt-i-RNA PCR 
(57.3% vs. 14.3%) for the detection of I? carinii f. sp. 
hominis DNA in patients with PCP Various hypotheses 
can be proposed to explain these different results,9~10 
such as the presence of a low number of DNA copies in 
blood, or a peculiar susceptibility (or lability) to serum 
DNAse of the specific target sequence, or possibly, the 
number of PCR cycles (70 vs. 40). In fact, nested PCR is 
estimated to be 30 to 50 times more sensitive than sin- 
gle-step PCR. l3 The proper collection and storage of bio- 
logic samples is essential to obtain amplification of I! 
carinii f. sp. hominis DNA from serum; a delay in freez- 
ing or storage at 4°C can cause a reduction of PCR pos- 
itive results. Examination of samples of positive serum, 
stored either at 4°C or at room temperature, 1,2,4,6, or 
10 days after storing, verified a rapid disappearance of I? 
carinii f. sp. hominis DNA, suggesting its peculiar labil- 
ity The possible presence of P carinii f. sp. hominis DNA 
Table 7. Genotypes Involved in Three Episodes of 
Pneumocystis carinii Pneumonia (PCP) Relapses: Either 
Reinfection (Genetic Switch) or Reactivation (Same Genotype) 
Patient 
I 
II 
Ill 
First PCP Episode Relapse 
AC AC 
BC Ab 
Bb Bbc 
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in serum as already fragmented free-floating DNA was 
demonstrated when researchers were unable to detect 
whole microorganisms in centrifuged serum and by the 
inhibitory effect of serum pretreatment with DNAse on 
subsequent amplification steps (data not presented). 
Data obtained from serum samples collected during 
follow-up of patients with PCP showed a strict relation 
between the acute phase of the disease and the presence 
of Pcarinii f. sp. hominis DNA in serum. Since blood can 
be easily collected and stored, ITSs nested PCR applied for 
the detection of I! carinii f. sp. hominis DNA on serum 
samples before the beginning of specific therapy makes 
this a highly specific (lOO%), even if moderately sensitive 
(57.3%) diagnostic tool, not just a useful means to follow 
the course of the disease. The detection of E! carinii f. sp. 
hominis DNA in PBMC as well as in serum, both in 
patients undergoing primary specific prophylaxis and in 
naive patients, could suggest that the occurrence of extra- 
pulmonary pneumocystosis (not observed in patients in 
the present study, at least by clinical and echographic 
examination) is attributable to preliminary blood-stream 
dissemination. Although the presence of I? carinii f. sp. 
hominis DNA in respiratory samples @AL) could, in some 
cases, demonstrate a subclinical colonization during other 
pulmonary infections, the positivity of serum seems to be 
exclusively related to acute PCP, suggesting greater dam- 
age to the interstitial-alveolar barrier. This would concur 
with the findings of Miyawaki et al3 but it is in contrast 
with the observations of other authors.9J3 These contra- 
dictory findings need further investigations for researchers 
to understand the real predictive or diagnostic value of the 
presence of I? carinii f. sp. hominis DNA in blood. The 
presence of I? carinii f. sp. hominis DNA in blood sam- 
ples (serum and PBMC) collected either from patients 
undergoing pentamidine aerosol as primary prophylaxis 
or from naive patients needs to be more carefully studied 
to determine whether this phenomenon spontaneously 
occurs during the disease or if it could be favored by iatro- 
genie procedures. 
The application of PCR on oropharyngeal washes, 
originally proposed with mt-i-RNA primers by Wakefield 
and colleagues,14 showed a sensitivity ranging from 56%; 
for PCR alone to 78% for PCR followed by oligoblotting: 
using IT!& nested PCR alone on oropharyngeal samples 
the present authors had similar results (69.1%).The high 
specificity of ITSs primers for &? carinii f. sp. hominis 
was further demonstrated by the absence of cross-reac- 
tions in the presence of oropharyngeal candidosis, in 
patients affected either by PCP or by other opportunis- 
tic pulmonary infections. 
The negativity for P carinii f. sp. hominis DNA on 
oropharyngeal washes collected from HIV-negative con- 
trols demonstrates an epidemiologic value, confirming 
the fact, described by other authors,‘5,16 that subjects 
working as health care personnel are not involved as res- 
piratory carriers for E! carinii f. sp. hominis. 
Combined analysis of the results obtained by ITSs 
nested PCR on serum, PBMC, and garglings demonstrated 
the presence of I! carinii f. sp. hominis DNA in all 
patients with PCP, since each of them had at least one 
positive noninvasive sample collected before bron- 
choscopy These results underline the possibility that ITSs 
nested PCR could have a clinical application for non- 
invasive diagnosis of PCP in AIDS patients. 
The possibility of typing different I? carinii f. sp. 
hominis genotypes by TSO hybridization, indeed, repre- 
sents a promising means to obtain more information for 
further studies about virulence and drug susceptibility. 
Preliminary results obtained after TSO hybridization on 
BAL and serum samples collected at different times sug- 
gest either a different genotype-related blood dissemina- 
tion or a subsequent clearance from blood during specific 
chemotherapy. The lack of hybridization observed by the 
authors could be explained by the recent finding of fur- 
ther variation among ITSs sequences, underlining the 
necessity of sequencing for l? carinii f. sp. hominis typ- 
ing, at least in “missed” isolates that cannot be properly 
typed by the TSO technique originally described by Lu 
et al.* Typing of Pcarinii f. sp. hominis isolates, after all, 
could be a useful epidemiologic tool to investigate the 
dynamics of relapses occurrence, demonstrating the pos- 
sibility of either endogenous reactivation (same geno- 
type) or reinfection (genetic switch), as described by 
other authors.17,18 
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